Canada markets closed

BetterLife Pharma Inc. (BETR.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.1000+0.0200 (+25.00%)
At close: 01:07PM EDT
Full screen
Previous Close0.0800
Open0.1000
Bid0.0800 x N/A
Ask0.1050 x N/A
Day's Range0.1000 - 0.1000
52 Week Range0.0800 - 0.3650
Volume6,848
Avg. Volume47,661
Market Cap8.54M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-0.1610
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference

    VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that Dr. Ahmad Doroudian, Chief Executive Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 1st Annual Mental Health Conference being held on June 27th, 2022 in New York Cit

  • GlobeNewswire

    BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

    VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract submitted on the anti-depressant activity of its lead compound 2-bromo-LSD (“BETR-001”) was accepted for poster presentation at the upcoming FENS Forum, being held July 9-13 in Paris,

  • GlobeNewswire

    BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference

    VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract on the preclinical data on anti-depressant activity of its lead compound 2-bromo-LSD (“BETR-001”) was accepted for presentation at the upcoming Canadian Association for Neuroscience